

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit [www.djreprints.com](http://www.djreprints.com).

<https://deloitte.wsj.com/cfo/frank-damelio-cfo-in-residence-on-creating-enterprise-value-9922626b>

LEADERSHIP | CAPEX | LIFE SCIENCES

# Frank D'Amelio, CFO-in-Residence, on Creating Enterprise Value

The retired CFO of Pfizer and active board member for several organizations discusses finance's central role in guiding capital allocation, monitoring processes, and the importance of owning expectations



Frank D'Amelio

Following a long career as CFO, Frank D'Amelio has a wealth of insights to offer the current and next generations of finance chiefs. His lessons and management perspectives draw on 15 years as CFO and executive vice president at Pfizer, where he oversaw the pharmaceutical company's worldwide global supply chain, the manufacture and distribution of its COVID-19 vaccine, and business development transactions worth nearly \$200 billion. During D'Amelio's term as Pfizer's CFO, the company's market cap increased by almost \$165 billion. That tenure followed more than two decades of finance and operational leadership, including serving as both COO and CFO at Lucent Technologies.

D'Amelio is currently the CFO-in-residence and independent advisor for Deloitte's CFO Program. He also serves as a director for Hewlett Packard

